202 related articles for article (PubMed ID: 36282417)
1. Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy.
Fung S; Shirley M
Drugs; 2022 Oct; 82(15):1541-1548. PubMed ID: 36282417
[TBL] [Abstract][Full Text] [Related]
2. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
Blay JY; Serrano C; Heinrich MC; Zalcberg J; Bauer S; Gelderblom H; Schöffski P; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Meade J; Shi K; Ruiz-Soto R; George S; von Mehren M
Lancet Oncol; 2020 Jul; 21(7):923-934. PubMed ID: 32511981
[TBL] [Abstract][Full Text] [Related]
3. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous
Bauer S; Heinrich MC; George S; Zalcberg JR; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Meade J; Su Y; Ruiz-Soto R; Blay JY; von Mehren M; Schöffski P
Clin Cancer Res; 2021 Dec; 27(23):6333-6342. PubMed ID: 34503977
[TBL] [Abstract][Full Text] [Related]
4. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
Janku F; Abdul Razak AR; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Somaiah N; Hu S; Rosen O; Su Y; Ruiz-Soto R; Gordon M; George S
J Clin Oncol; 2020 Oct; 38(28):3294-3303. PubMed ID: 32804590
[TBL] [Abstract][Full Text] [Related]
5. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
Zalcberg JR
Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
[TBL] [Abstract][Full Text] [Related]
6. Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.
Nemunaitis J; Bauer S; Blay JY; Choucair K; Gelderblom H; George S; Schöffski P; Mehren MV; Zalcberg J; Achour H; Ruiz-Soto R; Heinrich MC
Future Oncol; 2020 Jan; 16(1):4251-4264. PubMed ID: 31755321
[TBL] [Abstract][Full Text] [Related]
7. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
George S; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Razak AA; Gordon MS; Somaiah N; Jennings J; Meade J; Shi K; Su Y; Ruiz-Soto R; Janku F
Eur J Cancer; 2021 Sep; 155():236-244. PubMed ID: 34391056
[TBL] [Abstract][Full Text] [Related]
8. Ripretinib in treatment of repeatedly relapsing rectal gastrointestinal stromal tumor: a case report.
Wu C; Zhang J; Wu X
Ann Palliat Med; 2021 Apr; 10(4):4994-4998. PubMed ID: 33966435
[TBL] [Abstract][Full Text] [Related]
9. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Smith BD; Kaufman MD; Lu WP; Gupta A; Leary CB; Wise SC; Rutkoski TJ; Ahn YM; Al-Ani G; Bulfer SL; Caldwell TM; Chun L; Ensinger CL; Hood MM; McKinley A; Patt WC; Ruiz-Soto R; Su Y; Telikepalli H; Town A; Turner BA; Vogeti L; Vogeti S; Yates K; Janku F; Abdul Razak AR; Rosen O; Heinrich MC; Flynn DL
Cancer Cell; 2019 May; 35(5):738-751.e9. PubMed ID: 31085175
[TBL] [Abstract][Full Text] [Related]
10. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
Bauer S; Jones RL; Blay JY; Gelderblom H; George S; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Su Y; Meade J; Wang T; Sherman ML; Ruiz-Soto R; Heinrich MC
J Clin Oncol; 2022 Dec; 40(34):3918-3928. PubMed ID: 35947817
[TBL] [Abstract][Full Text] [Related]
11. Ripretinib: First Approval.
Dhillon S
Drugs; 2020 Jul; 80(11):1133-1138. PubMed ID: 32578014
[TBL] [Abstract][Full Text] [Related]
12. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
Zalcberg JR; Heinrich MC; George S; Bauer S; Schöffski P; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Somaiah N; Meade J; Reichert V; Shi K; Sherman ML; Ruiz-Soto R; von Mehren M; Blay JY
Oncologist; 2021 Nov; 26(11):e2053-e2060. PubMed ID: 34313371
[TBL] [Abstract][Full Text] [Related]
13. Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study.
Symcox M; Somaiah N
Future Oncol; 2021 Dec; 17(36):5007-5012. PubMed ID: 34661454
[TBL] [Abstract][Full Text] [Related]
14. Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
Sargsyan A; Kucharczyk MA; Jones RL; Constantinidou A
Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):119-127. PubMed ID: 36644853
[TBL] [Abstract][Full Text] [Related]
15. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.
Heinrich MC; Jones RL; George S; Gelderblom H; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Siontis BL; Goldstein D; Boye K; Sanchez C; Steeghs N; Rutkowski P; Druta M; Serrano C; Somaiah N; Chi P; Reichmann W; Sprott K; Achour H; Sherman ML; Ruiz-Soto R; Blay JY; Bauer S
Nat Med; 2024 Feb; 30(2):498-506. PubMed ID: 38182785
[TBL] [Abstract][Full Text] [Related]
16. [New drug approvals: Ripretinib for advanced gastrointestinal stromal tumors (GIST) in fourth or later-line therapy].
Lemaître J; Watson S
Bull Cancer; 2022 Mar; 109(3):250-252. PubMed ID: 35094842
[No Abstract] [Full Text] [Related]
17. KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape.
Mühlenberg T; Falkenhorst J; Schulz T; Fletcher BS; Teuber A; Krzeciesa D; Klooster I; Lundberg M; Wilson L; Lategahn J; von Mehren M; Grunewald S; Tüns AI; Wardelmann E; Sicklick JK; Brahmi M; Serrano C; Schildhaus HU; Sievers S; Treckmann J; Heinrich MC; Raut CP; Ou WB; Marino-Enriquez A; George S; Rauh D; Fletcher JA; Bauer S
J Clin Oncol; 2024 Apr; 42(12):1439-1449. PubMed ID: 38408285
[TBL] [Abstract][Full Text] [Related]
18. An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.
Patel SR; Reichardt P
Cancer; 2021 Jul; 127(13):2187-2195. PubMed ID: 33974733
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma.
Janku F; Bauer S; Shoumariyeh K; Jones RL; Spreafico A; Jennings J; Psoinos C; Meade J; Ruiz-Soto R; Chi P
ESMO Open; 2022 Aug; 7(4):100520. PubMed ID: 35753087
[TBL] [Abstract][Full Text] [Related]
20. Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.
Goggin C; Stansfeld A; Mahalingam P; Thway K; Smith MJ; Huang P; Jones RL; Napolitano A
Future Oncol; 2022 Aug; 18(26):2967-2978. PubMed ID: 35880452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
